The clearance to Insurance Products takes a lot of time in the country. Policyholders’ protection is the prime concern of the Insurance Regulatory and Development Authority (IRDA) and it does exercise a thorough diligence while approving products accordingly. IRDA has informed that the scrutiny process involves detailed examination of whether:

• Product is suitable to the targeted customers and meets their genuine needs.

• The reasonableness of cover provided and affordability in terms of premium charged.

• Financial viability of the product

• Compliance with various regulations/circulars/guidelines etc issued by the Authority

• The interests of all the stakeholders is protected, and

• The reinsurance arrangements, pricing assumptions, target segments, investment philosophy, charges (in case of unit linked products) etc, are appropriate.

A considerable time is spent in cross correspondence and discussion with the applicant company thereby constraining the pace of product clearances.

In order to address product design issues, the Authority had already initiated exposure drafts on various issues with respect to (i) Non-linked products, (ii) Linked Products and (iii) Health insurance products offered by both life and non-life insurers and has notified IRDA (Linked Insurance products) Regulations 2013, IRDA (Non-Linked Insurance products) Regulations 2013 and IRDA (Health Insurance) Regulations 2013. These regulations have been evolved to address divergent practices adopted by the insurers in the past thereby ensuring consistency in the products which may also result in speedy approval of products.

This was stated by Minister of State for Finance, Shri Namo Narain Meena, in written reply to a question in the Lok Sabha today.

DSM/RS/ka

(Release ID :95154)

Insurance product clearance focuses on policyholder protection and standardised regulations to streamline approvals. Clearance of insurance products is governed by regulatory scrutiny focused on policyholder protection, examining suitability to targeted customers, reasonableness and affordability of cover, financial viability, regulatory compliance, stakeholder interests, and appropriateness of reinsurance, pricing assumptions, target segments, investment philosophy and charges; consolidated regulations for linked, non linked and health products were introduced to harmonise practices and expedite approvals.